Helus Pharma's Q2 Results Highlight Phase 3 Progress and Pipeline Expansion

Helus Pharma reported a wider net loss but completed enrollment in its pivotal Phase 3 trial for HLP003, signaling progress toward addressing major depressive disorder.

Chicago Metrowire Staff
••Healthcare
Helus Pharma's Q2 Results Highlight Phase 3 Progress and Pipeline Expansion

Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) reported fiscal second-quarter 2027 financial results and business updates for the period ended Sept. 30, 2026, emphasizing continued advancement of its novel serotonergic agonist (NSA) pipeline. The company ended the quarter with $171.1 million in cash and a net loss of $103.1 million, compared with $33.7 million in the prior-year period. Operating expenses excluding share-based compensation rose to $39.6 million from $28.5 million, primarily due to the continued advancement of its Phase 3 clinical program. Cash used in operating activities totaled $35.3 million, compared with $34.5 million a year earlier.

The most significant operational milestone was the completion of enrollment in APPROACH, the company's pivotal Phase 3 study evaluating HLP003 as an adjunctive treatment for major depressive disorder (MDD). Enrollment also continued in the EMBRACE and EXTEND studies. Helus Pharma outlined plans to initiate a Phase 2 monotherapy study of HLP004 for generalized anxiety disorder in the first quarter of 2027 and expects to select a development candidate for its HLP005 program in the second half of 2027. For a detailed view of the full press release, visit https://ibn.fm/yu74F.

These developments matter because HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the adjunctive treatment of MDD, a status reserved for therapies that may offer substantial improvement over existing treatments. The completion of enrollment in APPROACH brings the company closer to potentially delivering a new class of treatment for depression, which remains a large unmet need. Helus Pharma is a clinical-stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company operates in Canada, the United States, the United Kingdom and Ireland. For more information, visit www.helus.com.

Investors seeking ongoing updates on Helus Pharma can access the company's newsroom through Helus Pharma. The announcement was disseminated via BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other services. The platform also offers editorial syndication to 5,000+ outlets and social media distribution to millions of followers. For full terms and disclaimers, see https://www.BioMedWire.com/Disclaimer.

Blockchain Registration

QR Code for Blockchain Registration